

Transformative Therapies for Neurodegenerative Diseases; MOU with Advanced Innovative Partners: GlobeStar : \$GSTC

RICHLAND, WASHINGTON, UNITED STATES, June 14, 2023

/EINPresswire.com/ -- Transformative Therapies for Neurodegenerative Diseases; MOU with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis: GlobeStar Therapeutics ([Stock Symbol: GSTC](#))

Biotechnology Leader in Transformative Therapies for the Management of Chronic Neurodegenerative Diseases.



Developing Project Amethyst™, a Compound Intended to Treat Neurodegeneration from Multiple Sclerosis (MS).

“

Given AIP's strong global relationships with universities, medical associations and hospitals, with its considerable experience in clinical trials, we are delighted that AIP will collaborate”

*James C. Katzaroff CEO of
GSTC*

Exclusive Worldwide Licensee for Project Amethyst™, Including All Patents and Patent Applications.

MOU Signed with Advanced Innovative Partners to Develop Clinical Studies for Project Amethyst™ Multiple Sclerosis Treatment.

GlobeStar Therapeutics Corporation ([OTC PINK:GSTC](#)) has a mission is to pioneer biotechnology in transformative therapies for the management of chronic neurodegenerative diseases. In an initial study of Project

Amethyst™ in Italy of 150 volunteers, 90 between 25 and 65 years of age with MS disease and 60


healthy volunteers, the average Expanded Disability Status Scale (EDSS) score for subjects with MS dropped by at least 1.3 points for pre-treatment and an average of 4.02 points after treatment. After 45 days of treatment, all subjects reported an improvement in balance and motor control of all extremities, and most reported an improvement in bladder control. GSTC is the exclusive global licensee of the Project Amethyst™ patents and patent applications.

MOU with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis Treatment


On June 14th GSTC and Advanced Innovative Partners (AIP), a clinical-stage pharmaceutical company focusing on the development of therapeutics and diagnostics, announced that they have entered into a memorandum of understanding (MOU) collaboration agreement to design and implement clinical trials for Project Amethyst™, a compound intended to treat neurodegeneration from Multiple Sclerosis (MS). GSTC is the exclusive worldwide licensee for Project Amethyst™, including all patents and patent applications relating thereto, including U.S. Patent #10610592.

Advanced Innovative Partners is a private clinical stage company focused on developing therapeutic and diagnostic radiopharmaceuticals for oncology, rare pediatric diseases, infectious disease and biomedical countermeasures. The company's robust nuclear medicine product portfolio includes specialty pharmaceuticals enabling personalized medicine. For additional information about AIP please visit www.advancedinnovativepartners.com

James C. Kataroff, President and CEO of GSTC stated, "Given AIP's strong global relationships with universities, medical associations and hospitals, with its considerable experience in clinical



\$GSTC Race to Erase MS



\$GSTC GlobeStar Therapeutics

trials, we are delighted that AIP will collaborate with GSTC to advance trials for Project Amethyst™. My relationship with AIP's founder, Stanley Satz extends over decades, and I am grateful for his and AIP's support."

Stanley Satz, PhD., AIP's Chairman and Chief Science Officer said: "Our team has considerable domestic and international experience implementing clinical trials for radiopharmaceuticals and other therapies with world renowned colleagues in the areas of oncology, rare pediatric diseases, infectious disease and biomedical countermeasures. We were impressed with the clinical results obtained in Italy for treatment of Multiple Sclerosis patients using Project Amethyst™. These results provide a good foundation for establishing more comprehensive clinical trials with AIP's partners. We are thrilled to advance the opportunities for Project Amethyst™."

The implementation of the Memorandum of Understanding is subject to the execution of definitive agreements and other customary conditions. After these conditions are met, the MOU contemplates that GSTC will lead the effort, contribute related rights to Project Amethyst™, and have primary responsibility for financing, supply chain, manufacturing, and sales, while AIP will introduce potential partners to collaborate in the clinical study, manufacturing and distribution.

For more information on GSTC visit: www.globestarterapeutics.com

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated \$500 by a third party for dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the

failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

SOURCE: CorporateAds.com

James C. Katzaroff, President and CEO
GlobeStar Therapeutics Corporation
+1 206-451-1970

[email us here](#)

Visit us on social media:

[Twitter](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/639445306>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.